Nonalcoholic fatty liver disease NAFLD is currently the most common liver disease worldwide, the prevalence of which had progressively increased over the past 10 years where other liver diseases remained at the same prevalence rates or are expected to decrease as in the case of hepatitis C virus HCV . The treatment of NAFLD is of prime concern to health care professionals and patients due to the significant mortality and morbidity it implies the problem is further escalated by the fact that standard of care medications targeting NAFLD remain experimental and without evidence base. Treatment nowadays is focused on lifestyle modification and managing the comorbid associated diseases, with a possible role for some hepatic protective agents. Medications include agents for weight loss, insulin sensitizers, drugs that reduce blood lipids, glucagon mimetics, drugs that may reduce fibrosis, angiotensin receptor blockers, and medicines believed to reduce endoplasmic reticular stress such as vitamin E, ursodeoxycholic acid, and S adenosyl methionine. Ursodeoxycholic acid UDCA is a metabolic by product of intestinal bacteria, showing hepatoprotective effects. However, its underlying molecular mechanisms remain unclear. The action mechanisms underlying the protective effects of UDCA and vitamin E against liver dysfunction using metabolomics and metagenomic analysis is common these days. Nonalcoholic fatty liver disease NAFLD is a leading cause of chronic liver disease.
Dr. Bharat Kumar Marmath | Dr. Meenakshi Mayanger Marmath "Non Alcoholic Fatty Liver Disease (NAFLD) Positive Correlation with Metabolic Disorders Has Positive Outcome with UDCA (Urso-Deoxy Cholic Acid) Associated with Life Style Modification" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-5 , August 2021,
URL: https://www.ijtsrd.com/papers/ijtsrd43812.pdf
callforpaperlifesciences, lifesciencesjournal, researchpapers
No comments:
Post a Comment